Skip to main content

Confronting AIDS Directions for Public Health, Health Care, and Research (1986) / Chapter Skim
Currently Skimming:

Appendix F. CDC Classification System for HIV Infections
Pages 320-325

The Chapter Skim interface presents what we've algorithmically identified as the most significant single chunk of text within every page in the chapter.
Select key terms on the right to highlight them within pages of the chapter.


From page 320...
... . tThe following persons served on the review panel: DS Burke, MD, RR Redfield, MD, Walter Reed Army Institute of Research, Washington, DC; J Chin, MD, State Epidemiologist, California Department of Health Services; LZ Cooper, MD, St Luke's-Roosevelt Hospital Center, New York City; JP Davis, MD, State Epidemiologist, Wisconsin Division of Health; MA Fischl, MD, University of Miami School of Medicine, Miami, Florida; G Friedland, MD, Albert Einstein College of Medicine, New York City; MA Johnson, MD, Dl Abrams, MD, San Francisco General Hospital; D Mildvan, MD, Beth Israel Medical Center, New York City; CU Tuezon, MD, George Washington University School.of Medicine, Washington, DC; RW Price, MD, Memorial Sloan-Kettering Cancer Center, New York City; C Konigsberg, MD, Broward County Public Health Unit, Fort Lauderdale, Florida; MS Gottlieb, MD, University of California-Los Angeles Medical Center; representatives of the National Institute of Allergy and Infectious Diseases, National Cancer Institute, National Institutes of Health; Center for Infectious Diseases, CDC.
Read the entire page →
From page 321...
... However, classification in the four principal groups, I-IV, is hierarchical in that persons classified in a particular group should not be reclassified in a preceding group if clinical findings resolve, since clinical improvement may not accurately reflect changes in the severity of the underlying disease. Group I includes patients with transient signs and symptoms that appear at the time of, or shortly after, initial infection with HTLV-111/LAV as identified by laboratory studies.
Read the entire page →
From page 322...
... Laboratory studies commonly indicated for patients with HTLV-111/LAV infection include, but are not limited to, a complete blood count (including differential white blood cell count) and a platelet count.
Read the entire page →
From page 323...
... Category C-2. Includes patients with symptomatic or invasive disease due to one of six other specified secondary infectious diseases: oral hairy leukoplakia, multidermatomal herpes poster, recurrent Salmonella bacteremia, nocardiosis, tuberculosis, or oral candidiasis (thrush)
Read the entire page →
From page 324...
... Sarngadharan MG, Groopman JE, et al~ Seroepidemiological studies of human Tlymphotropic retrovirus type 111 in acquired immunodeficiency syndrome. Lancet 1984;1:1438-40.
Read the entire page →
From page 325...
... Rota TR, Hirsch MS. Primary human Tlymphotropic virus type 111 infection.
Read the entire page →

Key Terms

  • clinical findings
  • secondary infectious
  • includes patients
  • surveillance definition
  • virus type

  • immunodeficiency syndrome
  • specified secondary
  • acquired immunodeficiency
  • clinical presentation
  • laboratory studies

  • disease subgroup
  • diseases listed
  • human immunodeficiency
  • human tlymphotropic
  • national reporting

  • presentation fulfills
  • findings resolve
  • walter reed
  • state epidemiologist
  • findings caused

  • acquired immune
  • generalized iymphadenopathy
  • invasive disease
  • persistent generalized
  • subgroup includes

  • disease due
  • clinical presentations
  • deficiency syndrome
  • immunodeficiency virus
  • epidemiologic studies


    • This material may be derived from roughly machine-read images, and so is provided only to facilitate research.
    More information on Chapter Skim is available.